This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Other respiratory distress of newborn신생아의 기타 호흡곤란

Contents and key points
ItemDetails
A. Classification codesICD-10: P22.8 (Other respiratory distress of newborn) | Special Copayment Reduction: V142 (severe intractable disease, 5 years)
B. SynonymsNo separate synonyms (encompasses other respiratory distress within the classification code)
C. Adult onsetNone — a group of diseases confined to the neonatal period (within 28 days of birth).
1. HistoryP22.8 is the residual code in ICD-10 encompassing causes of neonatal respiratory distress other than P22.0 (RDS) and P22.9 (unspecified respiratory distress); parallels the history of research on neonatal respiratory distress.
2. CausesCauses other than P22.0 such as transient tachypnea of the newborn (TTN), meconium aspiration syndrome (MAS), neonatal pneumonia, congenital airway malformations, air leak syndromes, and persistent pulmonary hypertension (PPHN).
3. GeneticsVaries with the causative disease; some congenital lung malformations have a genetic background.
4. General epidemiologyTTN: about 4-6/1,000 term infants; MAS: about 2/1,000; neonatal pneumonia: about 1-10/1,000; PPHN: about 1-2/1,000 live births.
5. PathophysiologyDiffers by cause; TTN - delayed lung fluid absorption, MAS - mechanical obstruction + inflammation, PPHN - persistent pulmonary vascular resistance, etc.
6. SymptomsTachypnea, chest retraction, grunting, cyanosis; onset time and pattern differ by cause.
7. SignsChest radiographic findings are the key to differentiating causes; blood gas analysis, echocardiography (PPHN evaluation).
8. ScreeningMonitoring of meconium-stained amniotic fluid; perinatal SpO₂ monitoring; detection of airway and lung malformations by prenatal ultrasound.
9. DiagnosisChest radiograph, arterial blood gas, echocardiography; bronchoscopy, CT, and genetic testing when needed.
10. TreatmentCause-specific treatment; CPAP, mechanical ventilation, inhaled nitric oxide (iNO), extracorporeal membrane oxygenation (ECMO), airway suctioning, antibiotics.
11. PrognosisTTN has a good natural course; MAS and PPHN have significantly increased mortality when severe; congenital malformations vary with the structural abnormality.
12. PreventionAirway management at delivery with meconium-stained fluid; induction of labor in post-term infants; delivery planning when prenatal ultrasound is abnormal.
13. ReferencesVain NE et al. Lancet 2004 and 9 other references

1. History

ICD-10 code P22.8 is a residual classification code encompassing "other respiratory distress of newborn," covering all causes of neonatal respiratory distress other than P22.0 (respiratory distress syndrome due to surfactant deficiency) and P22.9 (unspecified respiratory distress). Therefore this code is not a single disease but includes diverse causative diseases such as transient tachypnea of the newborn (TTN), meconium aspiration syndrome (MAS), neonatal pneumonia, persistent pulmonary hypertension of the newborn (PPHN), air leak syndromes (pneumothorax, pneumomediastinum), congenital lung malformations (congenital cystic adenomatoid malformation/CCAM, congenital pulmonary sequestration, bronchogenic cyst), and congenital diaphragmatic hernia (CHD).

Systematic research on neonatal respiratory distress began in the mid-20th century with the development of the neonatal intensive care unit (NICU). In the 1950s-60s RDS was the main focus of interest, but causes of respiratory distress other than it gradually came to be recognized as independent clinical entities. Transient tachypnea of the newborn (TTN) was described by Avery et al. in 1966 as an independent disease caused by delayed lung fluid absorption. The pathophysiology of meconium aspiration syndrome (MAS) was elucidated in the 1970s-80s, and protocols for airway suctioning in meconium-stained amniotic fluid have continued to evolve. In the 2004 randomized controlled trial by Vain et al., airway suctioning immediately after delivery in vigorous newborns was shown to give no benefit in preventing MAS, and delivery room management guidelines were revised.

Persistent pulmonary hypertension (PPHN) was recognized as an independent clinical syndrome in the late 1970s, and treatment reached a turning point in the 1990s when inhaled nitric oxide (iNO) was introduced as an effective selective pulmonary vasodilator. Extracorporeal membrane oxygenation (ECMO) for extremely severe PPHN developed as a last-resort treatment in the neonatal intensive care unit after Bartlett et al. reported the first successful case in 1975.


2. Causes

The main causative diseases included in P22.8 are as follows.

Transient tachypnea of the newborn (TTN)

One of the most common causes of respiratory distress in term or late preterm infants, caused by delayed absorption and clearance of fetal lung fluid after birth. Cesarean section without labor, male sex, maternal diabetes, large-for-gestational-age infants (macrosomia), administration of sedatives (anesthetics), and maternal asthma are risk factors. Catecholamines secreted during labor before delivery and the squeezing effect promote lung fluid absorption, and TTN occurs when these processes are blocked.

Meconium aspiration syndrome (MAS)

Occurs in term or post-term newborns by aspiration of meconium-contaminated amniotic fluid in utero or immediately after delivery. Meconium causes respiratory distress through mechanical obstruction (ball-valve effect), chemical pneumonitis, surfactant inactivation, and pulmonary vasoconstriction (inducing PPHN). Meconium-stained amniotic fluid occurs in about 10-15% of all deliveries, and MAS develops in about 2-9% of these. Post-term infants, intrauterine growth restriction (IUGR), and gestational hypertension are risk factors.

Neonatal pneumonia

The main causative organisms of early-onset (within 48 hours of birth) neonatal pneumonia are group B streptococcus (GBS), Escherichia coli (E. coli), Listeria, and so on, through vertical infection via the placenta, amniotic fluid, and birth canal. GBS pneumonia is very similar to RDS on chest radiograph and is difficult to differentiate. Late-onset (48 hours to 28 days after birth) pneumonia is caused by Staphylococcus aureus (S. aureus), gram-negative bacilli, and nosocomial organisms.

Persistent pulmonary hypertension of the newborn (PPHN)

A condition in which the normal decrease in pulmonary vascular resistance after birth does not occur or pulmonary vasoconstriction persists, so pulmonary blood flow is reduced and right-to-left shunting through the ductus arteriosus and foramen ovale continues. Various causes such as MAS, neonatal pneumonia, neonatal sepsis, hypoxia, and hypothermia can induce PPHN, and idiopathic PPHN also exists.

Air leak syndromes

Pneumothorax, pneumomediastinum, and pulmonary interstitial emphysema (PIE) occur from alveolar overdistension and rupture during mechanical ventilation or spontaneous breathing. Spontaneous pneumothorax occurs rarely even in term infants (about 1-2%), and a small asymptomatic pneumothorax resolves with conservative treatment.

Congenital lung and airway malformations

Structural abnormalities such as congenital pulmonary airway malformation (CPAM, formerly CCAM), congenital pulmonary sequestration, congenital bronchogenic cyst, and congenital diaphragmatic hernia (CDH) can cause neonatal respiratory distress. They may be already diagnosed on prenatal ultrasound or discovered by symptoms after birth.


3. Genetics

The genetic background of the other neonatal respiratory distress diseases included in P22.8 varies by cause.

TTN and MAS arise mainly from environmental and obstetric factors, and no clear genetic predisposition is known. However, there are studies suggesting that polymorphisms of ENaC (epithelial sodium channel, involved in lung fluid absorption)-related genes may affect susceptibility to TTN.

In PPHN, there are reports that polymorphisms of the eNOS (endothelial nitric oxide synthase) gene and the serotonin transporter (SERT) gene are associated with occurrence. SERT gene variants may increase the serotonin-mediated contractile response of pulmonary vascular smooth muscle cells and contribute to elevated pulmonary vascular resistance. In addition, there is epidemiological evidence that use of selective serotonin reuptake inhibitors (SSRIs) in late pregnancy increases the risk of neonatal PPHN.

Congenital diaphragmatic hernia (CDH) occurs mostly sporadically, but in about 10-15% it is accompanied by chromosomal abnormalities (trisomy 13, 18, 21) or single-gene variants (ZBTB16, COUP-TFII/NR2F2, GATA4, FOG2, etc.). The genetic etiology of CDH is currently being studied through whole exome sequencing.

Congenital pulmonary airway malformation (CPAM) is mostly sporadic, and abnormalities of the HNF1β and FGFR2 pathways have rarely been reported. Congenital pulmonary sequestration is also mostly sporadic, but chromosomal abnormalities accompany it in some.

Polymorphisms of innate immunity-related genes (TLR4, TLR2, MBL2, etc.) may be involved in susceptibility to neonatal pneumonia, but evidence for clinical use is limited.


4. General epidemiology

The epidemiological characteristics of each causative disease included in P22.8 are as follows.

The incidence of TTN is about 4-6 per 1,000 term infants and is 2-3 times higher in cesarean delivery than in vaginal delivery. The incidence is highest in elective cesarean section performed without labor. There is also a difference in incidence between cesarean section with labor and without labor, indicating that labor itself contributes to promoting lung fluid absorption.

MAS occurs in about 0.1-0.2% of all live births, and clinically significant MAS develops in 2-5% of newborns with meconium-stained amniotic fluid. The incidence is high in post-term infants (41 weeks or more). In developed countries the incidence is on a downward trend owing to policies of induction of labor in post-term infants and improved delivery management, but severe MAS is still a leading cause of NICU admission.

The incidence of neonatal pneumonia (early-onset) is reported worldwide at about 1-10 per 1,000 live births, and is higher in preterm and premature infants. Early-onset neonatal sepsis/pneumonia due to GBS has decreased greatly in developed countries with the implementation of prenatal GBS screening and intrapartum antibiotic prophylaxis.

PPHN occurs in about 1-2 per 1,000 of all live births and is often accompanied by severe MAS, CDH, and sepsis. Idiopathic PPHN occurs mainly in term infants. PPHN-related mortality reached 10-15% before the introduction of iNO and ECMO but has decreased markedly with modern treatment.

Spontaneous pneumothorax occurs in about 1-2 per 1,000 newborns and is often asymptomatic. Pneumothorax in preterm infants receiving mechanical ventilation has a higher incidence and is clinically serious.


5. Pathophysiology

Each causative disease of P22.8 has a different pathophysiology.

Mechanism of TTN

The fetal lung contains about 20-30 mL/kg of lung fluid, which is rapidly absorbed during normal delivery by active Na⁺ transport (via ENaC) driven by epinephrine and cortisol before delivery and by chest compression during delivery. In cesarean section or preterm delivery, this process is incomplete, and residual fluid in the lungs causes decreased lung compliance, ventilation-perfusion mismatch, and tachypnea. In the natural course it is absorbed through the pulmonary lymphatics and pulmonary capillaries and improves within 24-72 hours.

Mechanism of MAS

Meconium aspirated in utero or during delivery causes severe respiratory failure through ① mechanical obstruction of the bronchioles (ball-valve effect: air passes during inspiration but is blocked during expiration, causing air trapping), ② chemical pneumonitis due to bilirubin, fatty acids, and bile acids in meconium, ③ inhibition of surfactant function, and ④ pulmonary vasoconstriction (inducing PPHN). The inflammatory response to meconium induces a cytokine storm and neutrophil infiltration, aggravating lung injury.

Mechanism of PPHN

In the fetal circulation, pulmonary vascular resistance is high, so only about 10% of pulmonary blood flow passes through the lungs, and the rest is supplied directly to the systemic circulation by right-to-left shunting through the ductus arteriosus and foramen ovale. After birth, pulmonary vascular resistance normally decreases rapidly with lung expansion, increased oxygen, and release of prostacyclin and bradykinin. In PPHN this normal transition fails, so high pulmonary vascular resistance persists and the right-to-left shunt is maintained. A vicious cycle forms in which hypoxemia further promotes pulmonary vasoconstriction.


6. Symptoms

The diseases included in P22.8 commonly show general symptoms of respiratory distress such as tachypnea, chest retraction, and cyanosis, but there are characteristic differences according to each cause.

TTN: Tachypnea (60-100 breaths/min) immediately after birth or several hours later in term or late preterm infants is the main symptom, chest retraction is mild, and grunting is absent or mild. Cyanosis is easily corrected with supplemental oxygen. Symptoms resolve spontaneously within 24-72 hours.

MAS: Meconium staining appears on the skin, umbilical cord, and nails. The chest appears overinflated (barrel chest), and abnormal breath sounds (coarse crackles, decreased breath sounds) are heard on auscultation during both inspiration and expiration. In severe cases it progresses to PPHN with severe cyanosis and hypoxemia.

PPHN: Severe cyanosis and hypoxemia are characteristic, with poor response to oxygen administration. It was formerly called "persistent fetal circulation." A heart murmur (due to tricuspid regurgitation) and an anterior chest systolic murmur may be heard.

Pneumothorax: Sudden worsening of respiratory distress, abrupt fall in oxygen saturation, and bradycardia are characteristic. Unilaterally decreased breath sounds are heard, and mediastinal shift may appear in tension pneumothorax.


7. Signs

Chest radiographic findings are key to differentiating causes. In TTN, increased fan-shaped opacity centered on the hilum, thickening of the horizontal fissure, slight pleural effusion, and hyperinflation are characteristic. In MAS, patchy opacities and hyperinflation appear, and pneumothorax sometimes accompanies. Neonatal pneumonia (GBS) shows ground-glass opacity nearly identical to RDS and is difficult to differentiate by chest radiograph alone. Pneumothorax is confirmed by air shadow in the pleural cavity and lung collapse. In PPHN, in addition to chest radiographic findings of the underlying cause, pulmonary vascular markings may be decreased.

Echocardiography is essential for the diagnosis of PPHN. Pulmonary artery pressure is estimated using the peak tricuspid regurgitation (TR) velocity, and the direction of blood flow at the foramen ovale and ductus arteriosus (presence of right-to-left shunt) and right ventricular function are assessed. On arterial blood gas analysis, PPHN is characterized by poor improvement in PaO₂ even when inspired oxygen is raised to 100% (positive hyperoxia test: PaO₂ <150 mmHg on FiO₂ 1.0).


8. Screening

For MAS prevention, meconium-stained amniotic fluid is continuously monitored during delivery. Post-term infants (41 weeks or more) or fetuses with intrauterine growth restriction have a high risk of MAS, so intensive perinatal monitoring is needed. Since 2004, prophylactic airway suctioning in the delivery room is not recommended in newborns who cry and move vigorously, and is performed selectively only in newborns with respiratory distress or decreased muscle tone.

To prevent neonatal pneumonia due to GBS, GBS carrier screening is performed at 35-37 weeks of pregnancy, and penicillin or ampicillin prophylaxis during labor (intrapartum antibiotic prophylaxis) is given to positive mothers. This strategy has greatly reduced early-onset GBS sepsis/pneumonia.

Structural malformations such as congenital diaphragmatic hernia, CPAM, and sequestration are often detected on prenatal ultrasound (detailed ultrasound at 18-22 weeks of pregnancy) and are used for planning before delivery (place of delivery, preparation for immediate pediatric surgical intervention).


9. Diagnosis

The diagnosis of P22.8 is made by comprehensive consideration of clinical symptoms, perinatal history (meconium staining, mode of delivery, maternal infection risk), chest radiograph, and arterial blood gas analysis. Additional cause-specific tests include ① TTN: chest radiograph (hilar opacity, thickened horizontal fissure), confirming response to oxygen; ② MAS: meconium staining of skin and umbilical cord, chest radiograph (patchy opacities); ③ neonatal pneumonia: blood culture, CBC (leukocytosis or leukopenia, increased immature cell ratio), CRP/procalcitonin; ④ PPHN: echocardiography (estimating pulmonary artery pressure, shunt direction), pre-post ductal SpO₂ difference (>3-5% indicates a significant right-to-left shunt); ⑤ pneumothorax: chest radiograph (air in the pleural cavity), emergency evaluation by chest transillumination; ⑥ congenital malformations: chest and abdominal CT, bronchoscopy (airway malformations), abdominal ultrasound (CDH).

Differentiating RDS from GBS pneumonia is very difficult clinically. Judgment is made by comprehensively considering gestational age, antenatal risk factors (maternal fever, premature rupture of membranes), and infection markers (CRP, procalcitonin, CBC), and antibiotic treatment is given concurrently in uncertain cases.


10. Treatment

Treatment of each causative disease included in P22.8 differs by cause, and oxygen supply and respiratory support are the common basis.

TTN: Supplemental oxygen (nasal cannula, oxygen hood) and, in some cases, CPAP are sufficient in most cases, and it resolves spontaneously. The effect of diuretic administration has not been proven and it is not currently recommended.

MAS: Depending on severity, treatment is applied stepwise from simple oxygen supplementation to CPAP and mechanical ventilation. Surfactant administration (surfactant lavage) may be useful in MAS when surfactant function is inhibited. Antibiotics (ampicillin + gentamicin) are given when concomitant pneumonia is possible. When PPHN accompanies, the PPHN treatment below is given in parallel.

PPHN: Inhaled nitric oxide (iNO, 20 ppm) is a selective pulmonary vasodilator and the standard treatment for PPHN. If there is no response to iNO, phosphodiesterase-5 inhibitors (oral sildenafil), prostacyclin (inhaled iloprost), milrinone, and so on are additionally considered. When mechanical ventilation (including high-frequency oscillatory ventilation) fails and the response to iNO is poor, the indication for ECMO is evaluated.

Pneumothorax: A small asymptomatic pneumothorax can be managed conservatively with high-concentration oxygen (accelerating nitrogen reabsorption). In symptomatic or tension pneumothorax, percutaneous needle thoracentesis or chest tube insertion is performed immediately.

Neonatal pneumonia: Early-onset: empirical ampicillin + gentamicin, then adjust antibiotics according to culture results. When GBS is confirmed, penicillin G monotherapy. Late-onset: prescribe broad-spectrum antibiotics including coverage for methicillin-resistant Staphylococcus aureus (MRSA), then adjust.


11. Prognosis

TTN has a very good prognosis, resolving spontaneously within 24-72 hours in most cases, and long-term sequelae are rare. There are reports that in some it is associated with wheezing in infancy.

The prognosis of MAS differs greatly by severity. Mild cases improve within several days, but severe MAS with PPHN has a mortality of 5-10% and a risk of long-term neurodevelopmental sequelae. Survival has improved with aggressive treatment (surfactant, iNO, ECMO).

The prognosis of PPHN varies with the underlying cause and treatment response. Idiopathic PPHN responsive to iNO has a good prognosis, but PPHN accompanying CDH has a mortality of 30-50% together with pulmonary hypoplasia. Survivors are at risk of hearing loss and neurodevelopmental abnormalities.

Neonatal pneumonia has a good prognosis with early aggressive treatment, but the risk of mortality and sequelae increases when sepsis or meningitis accompanies.


12. Prevention

To prevent TTN, unnecessary cesarean section before labor is minimized, and when cesarean section is needed it is performed after 39 weeks where possible. To prevent MAS, a policy of early induction of labor in post-term infants (after 41-42 weeks) is implemented. At delivery of a newborn with meconium-stained amniotic fluid, a pediatrician's presence immediately after birth and immediate assessment of respiratory status are carried out. To prevent GBS pneumonia, GBS carrier screening at 35-37 weeks and prophylactic antibiotic administration before delivery to positive mothers are carried out. Congenital malformations are detected early on prenatal ultrasound and delivery at a specialized medical institution is planned.


13. References

  1. Vain NE, Szyld EG, Prudent LM, et al. Oropharyngeal and nasopharyngeal suctioning of meconium-stained neonates before delivery of their shoulders: multicentre, randomised controlled trial. Lancet. 2004;364(9434):597-602. DOI: 10.1016/S0140-6736(04)16852-9. PMID: 15313360.
  2. Wiswell TE, Gannon CM, Jacob J, et al. Delivery room management of the apparently vigorous meconium-stained neonate. Pediatrics. 2000;105(1 Pt 1):1-7. DOI: 10.1542/peds.105.1.1. PMID: 10617695.
  3. Konduri GG, Kim UO. Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr Clin North Am. 2009;56(3):579-600. DOI: 10.1016/j.pcl.2009.04.004. PMID: 19501694.
  4. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. N Engl J Med. 2000;342(7):469-474. DOI: 10.1056/NEJM200002173420704. PMID: 10675428.
  5. Schnapf BM. Oxygen saturation screening of newborns to detect critical congenital heart disease. J Perinatol. 2011;31 Suppl 1:S22-26. DOI: 10.1038/jp.2010.183. PMID: 21448203.
  6. Sweet DG, Carnielli VP, Greisen G, et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome: 2022 Update. Neonatology. 2023;120(1):3-23. DOI: 10.1159/000528914. PMID: 36863329.
  7. Reuter S, Moser C, Baack M. Respiratory distress in the newborn. Pediatr Rev. 2014;35(10):417-428. DOI: 10.1542/pir.35-10-417. PMID: 25274969.
  8. Avery ME, Gatewood OB, Brumley G. Transient tachypnea of newborn. Possible delayed resorption of fluid at birth. Am J Dis Child. 1966;111(4):380-385. PMID: 5908624.
  9. Wyckoff MH, Aziz K, Escobedo MB, et al. Part 13: Neonatal Resuscitation: 2015 American Heart Association Guidelines Update. Circulation. 2015;132(18 Suppl 2):S543-560. DOI: 10.1161/CIR.0000000000000267. PMID: 26473001.
  10. Nair J, Lakshminrusimha S. Update on PPHN: mechanisms and treatment. Semin Perinatol. 2014;38(2):78-91. DOI: 10.1053/j.semperi.2013.11.004. PMID: 24818304.